BR112017012400A2 - processo para fabricação de partículas de resinato de fenilefrina; partículas de resinato de fenilefrina e uso de partículas de resinato de fenilefrina em formulações farmacêuticas - Google Patents

processo para fabricação de partículas de resinato de fenilefrina; partículas de resinato de fenilefrina e uso de partículas de resinato de fenilefrina em formulações farmacêuticas

Info

Publication number
BR112017012400A2
BR112017012400A2 BR112017012400A BR112017012400A BR112017012400A2 BR 112017012400 A2 BR112017012400 A2 BR 112017012400A2 BR 112017012400 A BR112017012400 A BR 112017012400A BR 112017012400 A BR112017012400 A BR 112017012400A BR 112017012400 A2 BR112017012400 A2 BR 112017012400A2
Authority
BR
Brazil
Prior art keywords
phenylephrine resinate
resinate particles
phenylephrine
particles
manufacture
Prior art date
Application number
BR112017012400A
Other languages
English (en)
Other versions
BR112017012400A8 (pt
Inventor
Lee Der-Yang
A Koch Edward
Waldman Joel
Li Shun-Por
W Chen Vincent
Original Assignee
Johnson & Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer Inc filed Critical Johnson & Johnson Consumer Inc
Publication of BR112017012400A2 publication Critical patent/BR112017012400A2/pt
Publication of BR112017012400A8 publication Critical patent/BR112017012400A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

a presente invenção descreve partículas de fenilefrina adequadas para formas de dosagem sólidas, líquidas ou semissólidas.
BR112017012400A 2014-12-12 2015-12-11 Complexo fármaco-resina, partícula de liberação estendida, formulação farmacêutica, método para formar um complexo de fármaco-resina revestido e processo para a preparação de um complexo fármaco-resina BR112017012400A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462091096P 2014-12-12 2014-12-12
PCT/US2015/065154 WO2016094751A1 (en) 2014-12-12 2015-12-11 Process for manufacturing phenylephrine resinate particles; phenylephrine resinate particles; and use of phenylephrine resinate particles in pharmaceutical formulations

Publications (2)

Publication Number Publication Date
BR112017012400A2 true BR112017012400A2 (pt) 2018-04-24
BR112017012400A8 BR112017012400A8 (pt) 2022-08-09

Family

ID=55130033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012400A BR112017012400A8 (pt) 2014-12-12 2015-12-11 Complexo fármaco-resina, partícula de liberação estendida, formulação farmacêutica, método para formar um complexo de fármaco-resina revestido e processo para a preparação de um complexo fármaco-resina

Country Status (13)

Country Link
US (2) US20160166518A1 (pt)
EP (1) EP3229787A1 (pt)
JP (2) JP6720174B2 (pt)
KR (1) KR20170095939A (pt)
CN (2) CN106999433A (pt)
AU (1) AU2015360386B2 (pt)
BR (1) BR112017012400A8 (pt)
CA (1) CA2969473A1 (pt)
HK (1) HK1245155A1 (pt)
MA (1) MA41152A (pt)
MX (1) MX2017007596A (pt)
RU (1) RU2727204C2 (pt)
WO (1) WO2016094751A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3522890A4 (en) 2016-10-10 2020-06-03 Rhodes Pharmaceuticals L.P. RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
IL273904B1 (en) 2017-10-09 2024-04-01 Rhodes Pharmaceuticals Lp Medicinal resin components and methods for their production and use
CN113384521B (zh) * 2020-03-12 2023-03-28 中国科学院上海高等研究院 一种快速增溶去甲肾上腺素水溶液且有效抑制样品氧化的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
AU736308B2 (en) 1996-12-20 2001-07-26 Warner-Lambert Company Llc Antitussive drugs delivered by ion exchange resins
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US8343546B2 (en) 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
RU2435569C2 (ru) * 2006-03-16 2011-12-10 Трис Фарма, Инк. Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола
US20070231387A1 (en) * 2006-04-04 2007-10-04 Luigi Levi Film-coated solid dosage forms
RU2450803C2 (ru) 2006-06-01 2012-05-20 Шеринг Корпорейшн Фармацевтические композиции для пролонгированного высвобождения фенилэфрина
NZ573174A (en) 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
WO2008064192A2 (en) * 2006-11-21 2008-05-29 Mcneil-Ppc, Inc. Modified release analgesic suspensions
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
CN102119027A (zh) 2008-06-26 2011-07-06 麦克内尔-Ppc股份有限公司 含有药物活性剂的包衣颗粒
WO2010115015A1 (en) * 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition
US20130230587A1 (en) * 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
EP2726066B1 (en) * 2011-06-28 2021-03-31 Neos Therapeutics, LP Dosage forms of amphetamine for oral administration
AU2013217564B2 (en) 2012-02-07 2017-04-06 Johnson & Johnson Consumer Inc. Rapidly disintegrating coated tablets
US20140271891A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles and use thereof in pharmaceutical formulations
US20140271892A1 (en) 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles having good auc

Also Published As

Publication number Publication date
HK1245155A1 (zh) 2018-08-24
JP2020125344A (ja) 2020-08-20
KR20170095939A (ko) 2017-08-23
CN106999433A (zh) 2017-08-01
CN115068425A (zh) 2022-09-20
RU2017124229A3 (pt) 2019-04-16
RU2017124229A (ru) 2019-01-15
RU2727204C2 (ru) 2020-07-21
JP2017537132A (ja) 2017-12-14
CA2969473A1 (en) 2016-06-16
AU2015360386A1 (en) 2017-06-15
JP6720174B2 (ja) 2020-07-08
JP7016907B2 (ja) 2022-02-07
US20160166518A1 (en) 2016-06-16
MX2017007596A (es) 2018-03-09
US20210330614A1 (en) 2021-10-28
BR112017012400A8 (pt) 2022-08-09
AU2015360386B2 (en) 2021-02-25
MA41152A (fr) 2017-10-17
EP3229787A1 (en) 2017-10-18
WO2016094751A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
BR112016030787A2 (pt) entidade química, composição farmacêutica e seu uso
CL2017000817A1 (es) Triazolopirazinonas como inhibidores de pde1
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
BR112015032718A2 (pt) composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
BR112015024640A2 (pt) processo para a preparação de um polímero antibacteriano, polímero antibacteriano, uso do polímero e produto antibacteriano
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
BR112015001841A2 (pt) filete ou listra de segurança, processo para fazer o mesmo ,substrato de segurança, processo para fazer o mesmo , uso do filete ou listra de segurança e documento de segurança.
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
CO2017002472A2 (es) Formulación de acetato de abiraterona
BR112015031979A2 (pt) letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112017002662A2 (pt) processo para preparar furfural e/ou derivados de furfural.
BR112017003332A2 (pt) uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica
BR112017008854A2 (pt) partículas de cadotrila
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
DOP2016000152A (es) Quinazolin-thf-aminas como inhibidores de pde1.
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
BR112017012400A2 (pt) processo para fabricação de partículas de resinato de fenilefrina; partículas de resinato de fenilefrina e uso de partículas de resinato de fenilefrina em formulações farmacêuticas
BR112018005299A2 (pt) 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso
DOP2016000179A (es) Hexahidrofuropirroles como inhibidores de pde1
BR112015022975A2 (pt) partículas de resinato de fenilefrina
BR112016026814A2 (pt) 2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêutica
PH12015502029A1 (en) Phenylephrine resinate particles and use thereof in pharmaceutical formulations

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: CHENANGO ZERO LLC (US)

B25A Requested transfer of rights approved

Owner name: CHENANGO TWO LLC (US)

B25A Requested transfer of rights approved

Owner name: CURRAHEE HOLDING COMPANY INC. (US)

B25D Requested change of name of applicant approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]